Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.69% and +107.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?